Drug Profile
FG 3246
Alternative Names: Anti-CD46 antibody conjugate - Fortis Therapeutics; Anti-CD46 antibody drug conjugate - Fortis Therapeutics; FG-3246; FOR-46Latest Information Update: 04 Apr 2024
Price :
$50
*
At a glance
- Originator Fortis Therapeutics
- Developer Fortis Therapeutics; University of California at San Francisco
- Class Antineoplastics; Drug conjugates; Immunoconjugates
- Mechanism of Action Undefined mechanism
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Phase I/II Prostate cancer
- No development reported Multiple myeloma
Most Recent Events
- 03 Apr 2024 Updated efficacy data from a phase I trial in prostate cancer released by FibroGen
- 22 Nov 2023 Fortis Therapeutics completes the phase I trial in Prostate cancer (Metastatic disease, Second-line therapy, Hormone refractory) (IV) in the USA (NCT03575819)
- 26 Jun 2023 FibroGen plans a phase II trial in Prostate cancer (Metastatic disease, Hormone refractory) in 2H of 2024